Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Wolverine: PNT2258 in r/r DLBCL
NCT02226965Phase 2Completed
- Sponsor
- GSK
- Start
- Dec 2014
- Primary completion
- Jul 2016
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), Targeted Liposomes
- Countries
- 2
01
Overview
A Phase 2 trial of PNT2258 in diffuse large B-cell lymphoma (DLBCL), sponsored by GSK. Started Dec 2014; status: completed.
02
Drugs
PNT2258
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02226965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02226965.